The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP), the European Union (EU)’s drug regulatory agency, recommended the approval of 9 new medications, 3 of which are biosimilars, at its April 2017 meeting. The 3 recommended biosimilars are all products of Sandoz.
CHMP recommended granting marketing authorization for etanercept-szzs (Erelzi; a biosimilar of reference drug Enbrel), for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis, and pediatric plaque psoriasis. Etanercept-szzs, which inhibits tumor necrosis factor-alpha, will be available and injectable solution. (The EU approved another etanercept biosimilar, Benepali, in January 2016.) The 2 other recommended biosimilars, are follow-on biologics to rituximab (Rituxan in the US and MabThera in the EU): Rixathon and Riximyo, and are indicated for the treatment of non-Hodgkin’s lymphoma, RA, granulomatosis with polyangiitis, and microscopic polyangiitis. Rixathon has an additional indication for the treatment of chronic lymphocytic leukemia. Both Rixathon and Riximyo will be available as a 500-mg and 100-mg concentrate for infusion. (The EU approved another rituximab biosimilar, Truxima, in February 2017.)
CHMP also recommended 2 orphan medications for the treatment of 2 different rare neurodegenerative conditions in children. Biogen’s nusinersen (Spinraza), indicated for the treatment of spinal muscular atrophy (SMA), was reviewed under an accelerated assessment program. There is currently no approved treatment for SMA in the EU. The second orphan pediatric drug to be recommended was BioMarin Pharmaceutical’s cerliponase alfa (Brineura), for the treatment of neuronal ceroid lipofuscinosis (CLN2) type 2 disease. Brineura was also reviewed under an accelerated assessment program. There are currently no medicines approved for CLN2 treatment, only options that address symptoms.
The other recommended medications are:
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.